Rasna Therapeutics, Inc. (RASP)

USD 0.0

(0.0%)

Market Cap (In USD)

3.08 Million

Revenue (In USD)

-

Net Income (In USD)

-4.44 Million

Avg. Volume

487.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.0E-4-0.039
PE
-
EPS
-
Beta Value
-64.361
ISIN
US7538881068
CUSIP
753888106
CIK
1582249
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Keeren Shah
Employee Count
-
Website
https://www.rasna.com
Ipo Date
2015-02-24
Details
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.

More Stocks